Eli Lilly launched an ad campaign on Friday, cautioning patients against the risks of unapproved weight-loss drugs in its ...
Altimmune's pemvidutide shows promise in treating MASH and obesity, with upcoming Phase 2b results poised to shape its market ...
Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.
The GLP-1 ad wars “Healthy Skepticism” comes weeks after Eli Lilly competitor and Ozempic-maker Novo Nordisk launched a print ...
Rare Disease Day, an annual gathering hosted by the FDA and National Institutes of Health, was postponed. Medicare spending on 10 diabetes drugs, including popular GLP-1s, more than quadrupled over a ...
Once again, Eli Lilly is using Hollywood’s biggest night as a platform to speak out on a hot-button issue in pharma. | Once ...
Eli Lilly announced plans for four new pharmaceutical manufacturing sites to produce domestic medicine production in the ...
FDA reform needs to be underpinned by strategy, not ‘indiscriminate’ cuts The Trump administration could save the lives of ...
The approval of etanercept for juvenile idiopathic arthritis in 1999 heralded a new era for children with arthritis. However, ...
At the four new sites, Lilly expects to create more than 3,000 jobs for engineers, scientists, operations personnel, and lab technicians.
Outsourcing Facilities Association and North American Custom Laboratories allege the FDA removed semaglutide from its ...
It was FDA approved based on a clinical trial that showed it, overall, delayed the onset of insulin dependence from two years ...